Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + RCHOP in Untreated DLBCL
NCT02541565Phase 1Completed
- Sponsor
- University of Washington
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by University of Washington. Primary endpoint: Number of Participants With a Grade 3 or Higher Toxicity. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02541565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02541565.